TPST (Tempest Therapeutics) Other Long-Term Liabilities : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Other Long-Term Liabilities?

Tempest Therapeutics's other long-term liabilities for the quarter that ended in Sep. 2024 was $0.00 Mil.

Tempest Therapeutics's quarterly other long-term liabilities increased from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($0.00 Mil) but then declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

Tempest Therapeutics's annual other long-term liabilities declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Tempest Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Tempest Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Other Long-Term Liabilities Chart

Tempest Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Tempest Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Long-Term Liabilities	Get a 7-Day Free Trial													-	-	-	-	-

Tempest Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Tempest Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

3OS:Germany

Address

2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005

Website

https://www.tempesttx.com

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Executives

Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Stephen R Brady	director, officer: Chief Executive Officer	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Samuel Whiting	officer: Chief Medical Officer	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Justin Trojanowski	officer: Corporate Controller	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas	officer: VP of Strategy and Finance	7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Ventures Vi Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky	director, officer: President	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710